Go Omura

Go Omura

Auto-generated profile, based on publicly available information

Go Omura

Department of Head and Neck Surgery National Cancer Center Hospital Tokyo Japan

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Auris Nasus Larynx
Verified
Journal Article
Closed access
GOGo Omura
Go Omura
KWKenta Watanabe
Kenta Watanabe
YFYoshinori Fujishiro
Yoshinori Fujishiro
YEYasuhiro Ebihara
Yasuhiro Ebihara
KNKazunari Nakao
Kazunari Nakao
TATakahiro Asakage
Takahiro Asakage

18 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TMTakashi Matsuki
Takashi Matsuki
IOIsaku Okamoto
Isaku Okamoto
CFChihiro Fushimi
Chihiro Fushimi
HTHideaki Takahashi
Hideaki Takahashi
TOTakuro Okada
Takuro Okada
TYTaku Yamashita
Taku Yamashita
No real-world, long-term outcomes of immunotherapy with nivolumab for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have yet been reported. Furthermore, the prognostic impact of the best overall response (BOR) of this therapy remains unclear. We conducted a multi-institutional cohort study of the long-term efficacy and safety of this therapy and investigated prognostic factors associated with survival. Further, we evaluated the relationship between BOR and survival. Median follow-up time was 25.9 months. Median overall survival (OS) was 9.6 months, and two-year survival rate was 25.0%. Median progression-free survival (PFS) was 3.7 months, and two-year PFS rate was 19.6%. BOR was assessed as complete response (CR) in 6%, partial response (PR) in 13%, stable disease (SD) in 30%, and progressive disease (PD) in 52% of the patients. Overall response rate was 18%, and disease control rate was 48%. For immune-related adverse events (irAEs), 38 irAEs were detected in 29 patients. On multivariate analysis, the development of irAEs was significantly associated with better OS and PFS. Better BOR was significantly associated with longer OS and PFS. These findings demonstrate the long-term efficacy and safety of nivolumab therapy for R/M SCCHN in a real-world setting. The magnitude of BOR and the development of irAEs might be useful surrogate markers of survival.

29 June 2022 in Auris Nasus Larynx
Verified
Journal Article
Closed access
GOGo Omura
Go Omura
YHYoshitaka Honma
Yoshitaka Honma
YMYoshifumi Matsumoto
Yoshifumi Matsumoto
TSTakeshi Shinozaki
Takeshi Shinozaki
MIMai Itoyama
Mai Itoyama
SYSeiichi Yoshimoto
Seiichi Yoshimoto

28 March 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
GOGo Omura
Go Omura
YSYuki Saito
Yuki Saito
MAMizuo Ando
Mizuo Ando
KKKenya Kobayashi
Kenya Kobayashi
YEYasuhiro Ebihara
Yasuhiro Ebihara
TATakahiro Asakage
Takahiro Asakage

28 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GOGo Omura
Go Omura
MAMizuo Ando
Mizuo Ando
YEYasuhiro Ebihara
Yasuhiro Ebihara
YSYuki Saito
Yuki Saito
KKKenya Kobayashi
Kenya Kobayashi
Tatsuya YamasobaTatsuya Yamasoba
Tatsuya Yamasoba
TP53 is the most frequently mutated gene in human cancers. Previous studies reported that TP53 mutations correlated with poor prognoses in patients with head and neck squamous cell carcinoma (HNSCC). However, the relationship between TP53 mutations and hypopharyngeal squamous cell carcinoma (HPSCC) is not known. The current study aimed to evaluate TP53 mutation status as a predictive biomarker in patients with HPSCC. We retrospectively reviewed the clinical charts of 57 HPSCC patients treated with initial surgery between 2008 and 2014. TP53 mutation status was determined by Sanger sequencing, and patients were classified into wild-type, missense mutation, and truncating mutation groups. Additionally, p53 expression was determined using immunohistochemistry in surgical specimens. TP53 mutations were identified in 39 (68%) patients. The 3-year disease-specific survival (DSS) rate of wild-type, missense mutation, and truncating mutation group were 94%, 61%, and 43%, respectively. The TP53 mutation group displayed significantly worse DSS and overall survival rates than the wild-type group (P = 0.01 and P = 0.007, respectively). Multivariate analyses revealed that the presence of TP53 mutations and ≥4 metastatic lymph nodes were independent adverse prognostic factors for HPSCC. p53 immunopositivity was detected in 22 patients, including 5 (28%) and 17 (71%) patients in the wild-type and missense mutation groups, whereas none of the patients with truncating mutation exhibited p53 immunopositivity (P = 0.0001). The TP53 mutation status correlated with poor prognosis in surgically treated HPSCC patients. Specifically, truncating mutations which were not detected by p53 immunohistochemistry were predictive of worst survival.

21 October 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
GOGo Omura
Go Omura
MAMizuo Ando
Mizuo Ando
YSYuki Saito
Yuki Saito
KKKenya Kobayashi
Kenya Kobayashi
TYTatsuya Yamasoba
Tatsuya Yamasoba
TATakahiro Asakage
Takahiro Asakage